WORLD-SURF-LEAGUE
10.3.2016 00:01:11 CET | Business Wire | Press release
Today the World Surf League and Corona announced a multi-year partnership agreement through 2018, making Corona the Official Beer of the World Surf League globally, with the exception of the U.S. market.
“2015 was the single biggest year in surfing history across every major metric we measure, and we are thrilled that Corona – one of the Top 10 most valuable beer brands in the world according to BrandZ 2015 – has chosen to partner with us,” said Mark Noonan, Global Chief Commercial Officer of the World Surf League. “Corona’s aspirational lifestyle is a perfect complement to the WSL, and we are extremely proud to have them join our group of world class partners.”
The WSL and Corona will work together on consumer and customer activations in all key markets aligning Corona’s authentic and unpretentious lifestyle with the World Surf League’s mission of putting the world’s best surfers on the world’s best waves. Corona will engage surf fans through compelling original content, exciting on-site activations like the Corona Sunsets festivals, and corporate social responsibility initiatives at some of the most exotic and remote locations on the planet.
“Corona has been popular with surfers since the early 1980s, when surfers first discovered the point breaks of Baja and regularly enjoyed a crisp, refreshing Corona after catching the waves. We see The World Surf League as a great ambassador for our brand and the Corona lifestyle,” said Global VP Corona Marcel Marcondes. “Corona reminds us all to take a step back, reconnect to our essential nature and enjoy moments outside. This partnership with the WSL creates an abundance of such special moments in the most beautiful settings all year long. We believe the WSL provides us with a valuable opportunity to connect with the WSL’s growing community and LDA fans that are inspired by the surf lifestyle.”
Corona will partner with WSL Championship Tour surfers Coco Ho, Alejo Muniz, Matt Wilkinson and Julian Wilson. At each stop of the WSL Championship Tour, Corona will help ensure the experience of fans is unforgettable. Key markets for brand activations in 2016 will include Australia, Brazil, South Africa and France.
The 2016 Samsung Galaxy World Championship Tour begins with the Quiksilver Pro in Australia, kicking-off on March 10. Fans can catch all the live action by going to worldsurfleague.com or by downloading the free app in either the iTunes store or Google Play.
About The World Surf League
The World Surf League (WSL), formerly the Association of Surfing Professionals (ASP), is dedicated to celebrating the world’s best surfing on the world’s best waves through a variety of best-in-class audience platforms. The League, headquartered in Santa Monica, is a truly global sport with regional offices in Australasia, Africa, North America, South America, Hawaii, Japan and Europe.
The WSL has been championing the world's best surfing since 1976, running global events across the Samsung Galaxy Men's and Women's Championship Tours, the Big Wave Tour, Qualifying Series, Junior and Longboard Championships, as well as the WSL Big Wave Awards. The League possesses a deep appreciation for the sport's rich heritage while promoting progression, innovation and performance at the highest levels.
Showcasing the world's best surfing on its digital platform at WorldSurfLeague.com as well as the free WSL app, the WSL has a passionate global fan base with millions tuning in to see world-class athletes like Mick Fanning, John John Florence, Stephanie Gilmore, Greg Long, Gabriel Medina, Carissa Moore, Makua Rothman, Kelly Slater, Adriano de Souza and more battle on the most unpredictable and dynamic field of play of any sport in the world.
For more information, please visit WorldSurfLeague.com .
About Corona
Corona is the leading beer brand in Mexico, the 6th most valuable beer brand in the world*, and the most popular Mexican beer worldwide, with sales in more than 120 countries. Corona Extra was first brewed in 1925 at the Cervecería Modelo in Mexico City. Ten years after its launch, Corona became the best-selling beer in Mexico, and today continues to stand for Mexican pride around the world. Follow global Corona on Instagram: @corona
View source version on businesswire.com: http://www.businesswire.com/news/home/20160309006234/en/
Contact:
World Surf League
Patty Smith, 310-804-2721
psmith@worldsurfleague.com
or
Corona
Karen
Couck
karencouck@ab-inbev.com
or
Kathleen
Van Boxelaer
kathleen.vanboxelaer@ab-inbev.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 07:30:00 CET | Press release
Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob
Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 06:30:00 CET | Press release
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan
VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 01:00:00 CET | Press release
Enabling Next-Generation High-Performance Automotive Camera Systems VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise
Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 22:30:00 CET | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 22:30:00 CET | Press release
Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom